Objective To observe the postoperative analgesic effects of perioperative intravenous parecoxib in gerontal patients undergoing laparoscopic cholecystectomy. Methods A prospective,randomized, double-blind, placebo-controlled, parallel group study was performed. The 40 American Society of Anesthesiologists (ASA) Ⅰ or Ⅱ patients (aged 60-80 years) undergoing elective laparoscopic cholecystectomy under general anesthesia were randomly allocated to 2 groups (n = 20,each): the parecoxib group received intravenous parecoxib 40 mg at 10 minutes before incision and 12 hours and 24 hours after incision; however, the placebo group received 5 ml normal saline instead of parecoxib at the same time. The intensity of algesia was measured using visual analogue scale (VAS)scores (1-10, 0 = no pain, 10 = worst pain), and was recorded at 2, 4, 6, 12, 24 hours after operation. The patients' global evaluation of postoperative analgesia was recorded and compared between the two groups. Results The VAS scores at the different time points were significantly less in parecoxib group than in placebo group (all P＜ 0.05). The patients' global evaluation of postoperative analgesia was higher in parecoxib group than in placebo group [(8. 1 ± 1.2) scores vs.(5.2± 0. 9 ) scores, t = 7. 402, P ＜ 0. 05]. Conclusions Intravenous parecoxib can effectively relieve postoperative algesia and improve postoperative analgesia after laparoscopic cholecystectomy.

Parkinson's disease (PD) is a common neurodegenerative disorder with typical motor symptoms and a variety of non-motor symptoms,including neuropsychiatric symptoms,autonomic dysfunctions,abnormal sense,sleep disorders and fatigue.Studies showed that several non-motor symptoms,such as olfactory dysfunction,constipation,rapid eye movement sleep behavior disorder,depression and fatigue,can occur before the onset of motor symptoms.Fatigue has been considered as one of the most disabling symptoms,and it has a significant impact on activity of daily living and quality of life,and brings heavy burdens to caregivers.However,fatigue in PD has no special biomarkers,so clinicians are lack of the recognition and intervention.Here,we will expound the prevalence,risk factors,rating scales and potential mechanism relating to neuropathology,neuroinflammation and neurobiochemistry in PD patients with fatigue.

Objective: To study the clinical effect of acupuncture combined with methylcobalamin in the treatment of diabetic peripheral neuropathy. Methods: Seventy-five diabetic patients complicated with peripheral neuropathies were included and randomly allocated into a treatment group (40 cases) and a control group (35 cases). The patients in the treatment group all received acupuncture therapy plus methylcobalamin. In the control group, patients only received methylcobalamin for treatment. The therapeutic effect was evaluated 4 weeks later. Results: Both of the two groups presented improvement in nervous symptoms, signs and nerve conduction, and the improvement of the treatment group was significantly better than that of the control group (P<0.05). Conclusion: The therapy of acupuncture in combination with methylcobalamin is more effective than the monotherapy with methylcobalamin in the treatment of diabetic peripheral neuropathy.

Flowering is one of the most important progresses for most plants during the transition from vegetative growth to reproductive growth. There are many factors that affect the flowering, including two main external factors, light and temperature, and the internal factors such as gibberellin acid (GA) and autonomous elements. At present, the late-flowering mutants are fallen into four pathways: photoperiod pathway, vernalization pathway, autonomous pathway and GA pathway according to factors described above. Through several floral integrators, such as SOC1, FT and LFY, the multiple flowering regulatory pathways control the flowering finely under the variable environmental condition and physiological condition.

0.05 ). Conclusion FTY720 is an effective specific and reversible immunosuppressant.

The determination of pantothenic acid in infant formula was carried out by means of HPLC. The sample was dissolved in deionizid water and put in an ultra-sonic generator for 15 minutes, adjust pH to precipitate protein. After centrifugation the supernatants were used as test sample for HPLC analysis. Column: Bondapak C18, Detector: ultraviolet 200nm, and 0.01M KH2PO4/CH3OH as eluant. Coefficient of variation was 6.58% and recovery was 93.78%.The method might be applicable to milk and milk products and alsoto the samples containing free pantothenic acid such as wheat germ and flour.

The monosialic acid ganglioside GM1 is rich in brain, which participates in the development process of the nerve system and plays wide neuroprotective roles. This article reviews recent reports about six neuroprotective mechanisms including: activating tyrosine kinase receptor——Trk receptor, modulating Ca 2+ homeostasis in cells, reducing the deposition of A? and its toxic roles in brain, inhibiting the production of reactive oxygen species, enhancing the activity of Na+,K+-ATPase.

To explore the detection of GNAS1 gene mutation from peripheral blood and non-involved bone marrow in patients with fibrous dysplasia of bone(FD). Both peripheral blood and non-involved bone marrow collected from six FD patients were used for genetic diagnosis by next generation sequencing and direct sequencing respectively. Two patients were found to have common gene mutation(positive) by next generation sequencing, accounting for 33.3% of total six people: p.R201H(CGT>CAT) was detected in both peripheral blood and bone marrow of patient No.3, and p.R201C(CGT>TGT) was detected in both tissues of patient No.6. While direct sequencing only found p.R201H(CGT>CAT) mutation in peripheral blood and bone marrow of patient No.3. Detection of GNAS1 gene mutation may contribute to the diagnosis of FD. Hot spot mutations of GNAS1 are present in peripheral blood and non-involved bone marrow samples from some Chinese FD patients, but the diagnostic value and sensitivity of GNAS1 gene mutation in non-involved tissues of FD patients is low by next generation sequencing or direct sequencing.

Objective To mvestigate the effect of phospholated-ERKl/2 on NF-κB p65 expresson nn the substania nigra(SN) of l-msthyi-4-phenyi-l,2, 3, 6-tetrahydropyeidine (MPTP)-induced mouse model of Parkinson's disease(PD). Methods PD mouse model was induced by MPTP and the behavoor of mouse was observed. Immunohistochemistry and Western bloiting analysis were used to observe the changes in expression of tyrosine hydroxylase (TH), NF-κB p65 and p-ERKl/2 in the SN of midbrain. Meanwhite, the above changes were also observed after treatment with U0126, a specific inhibitor of ERK. Results 1 h after the third MPTP administration, there were much more p-ERKl/2 positive cells than NF-κB p65 positive cells in the SN. 24 h after the fifth injection of MPTP, NF-κB p65 positive cells were significantly increased and p-ERKl/2 positive celiswere decreased, accompanted by marked loss of TH positive neurons. The above changes were greatly alleviated in animais treated with U0l26. Conclusion ERKl/2 pathway may regulate NF-κB p65 activation in MPTP-induced mouse model of Parkinson's disease, which leads to loss of dopamine neurons.